HRP20210707T1 - Prolinom blokirani označeni peptidi i njihova uporaba - Google Patents
Prolinom blokirani označeni peptidi i njihova uporaba Download PDFInfo
- Publication number
- HRP20210707T1 HRP20210707T1 HRP20210707TT HRP20210707T HRP20210707T1 HR P20210707 T1 HRP20210707 T1 HR P20210707T1 HR P20210707T T HRP20210707T T HR P20210707TT HR P20210707 T HRP20210707 T HR P20210707T HR P20210707 T1 HRP20210707 T1 HR P20210707T1
- Authority
- HR
- Croatia
- Prior art keywords
- substituted
- unsubstituted
- polypeptide
- image
- independently
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title claims 24
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 24
- 229920001184 polypeptide Polymers 0.000 claims 23
- 150000003839 salts Chemical class 0.000 claims 8
- 125000001931 aliphatic group Chemical group 0.000 claims 7
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 125000002252 acyl group Chemical group 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000006239 protecting group Chemical group 0.000 claims 3
- 150000001413 amino acids Chemical group 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000002462 isocyano group Chemical group *[N+]#[C-] 0.000 claims 2
- 125000005647 linker group Chemical group 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 239000011347 resin Chemical group 0.000 claims 2
- 229920005989 resin Chemical group 0.000 claims 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims 1
- 125000004450 alkenylene group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000004419 alkynylene group Chemical group 0.000 claims 1
- 150000001371 alpha-amino acids Chemical class 0.000 claims 1
- 235000008206 alpha-amino acids Nutrition 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 125000000732 arylene group Chemical group 0.000 claims 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 125000004474 heteroalkylene group Chemical group 0.000 claims 1
- 125000005549 heteroarylene group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Analytical Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
Claims (14)
1. Polipeptid naznačen time što polipeptid ima formulu (I) ili (II):
[image]
ili
[image]
ili njegova sol ili stereoizomer;
pri čemu:
svaka instanca K, L, M, L1, i L2 je, neovisno, nesupstituirani C1-6 alkilen;
Ra je vodik; supstituirani ili nesupstituirani alifatski; supstituirani ili nesupstituirani heteroalifatski; supstituirani ili nesupstituirani aril; supstituirani ili nesupstituirani heteroaril; supstituirani ili nesupstituirani acil; smola; amino zaštitna skupina; oznaka kojoj je opcionalno pridružen linker , pri čemu je linker skupina koja se sastoji od jedne ili više kombinacija supstituiranog ili nesupstituiranog alkilena; supstituiranog ili nesupstituiranog alkenilena; supstituiranog ili nesupstituiranog alkinilena; supstituiranog ili nesupstituiranog heteroalkilena; supstituiranog ili nesupstituiranog heteroalkenilena; supstituiranog ili nesupstituiranog karbociklena; supstituiranog ili nesupstituiranog heterociklena; supstituirani ili nesupstituirani arilena; ili supstituirani ili nesupstituirani heteroarilen;
Rb je -RB, -ORB, -N(RB)2, ili -SRB, pri čemu svaka instanca RB je, neovisno, vodik; supstituirani ili nesupstituirani alifatski; supstituirani ili nesupstituirani heteroalifatski; supstituirani ili nesupstituirani aril; supstituirani ili nesupstituirani heteroaril; supstituirani ili nesupstituirani acil; smola; prikladna hidroksilna, amio ili tiol zaštitna skupina; ili dvije RB skupine zajedno koje formiraju 5- do 6-člani heterociklični ili heteroaromatski prsten;
svaka instanca RKL, RLL, i RLM je, neovisno, vodik; supstituirani ili nesupstituirani alifatski; supstituirani ili nesupstituirani heteroalifatski; supstituirani ili nesupstituirani aril; supstituirani ili nesupstituirani heteroaril; supstituirani ili nesupstituirani acil; supstituirani ili nesupstituirani hidroksil; supstituirani ili nesupstituirani tiol; supstituirani ili nesupstituirani amino; azido; cijano; izocijano; halo; ili nitro;
svaka instanca Rd je, neovisno, vodik; supstituirani ili nesupstituirani alifatski; supstituirani ili nesupstituirani heteroalifatski; supstituirani ili nesupstituirani aril; supstituirani ili nesupstituirani heteroaril; supstituirani ili nesupstituirani acil; ili Rd je amino zaštitna skupina;
svaka instanca Re je, neovisno, prikladni bočni lanac aminokiselina; vodik; supstituirani ili nesupstituirani alifatski; supstituirani ili nesupstituirani heteroalifatski; supstituirani ili nesupstituirani aril; supstituirani ili nesupstituirani heteroaril; supstituirani ili nesupstituirani acil; supstituirani ili nesupstituirani hidroksil; supstituirani ili nesupstituirani tiol; supstituirani ili nesupstituirani amino; cijano; izocijano; halo; ili nitro;
svaka instanca G je, neovisno, prirodna ili neprirodna aminokiselina ili skupina formule:
[image]
[image]
[image]
[image]
ili
[image]
.
pri čemu:
n je 1, 2, ili 3; i
svaka instanca R1 i R2 je neovisno vodik; supstituirani ili nesupstituirani alifatski; supstituirani ili nesupstituirani heteroalifatski; supstituirani ili nesupstituirani aril; supstituirani ili nesupstituirani heteroaril; supstituirani ili nesupstituirani acil; supstituirani ili nesupstituirani hidroksil; supstituirani ili nesupstituirani tiol; supstituirani ili nesupstituirani amino; ili halo, ili R1 i R2 su spojeni u karbociklički ili heterociklički prsten;
svaka instanca R3 i R4 je, neovisno, vodik; supstituirani ili nesupstituirani alifatski; supstituirani ili nesupstituirani heteroalifatski; hidroksilna zaštitna skupina kada je vezana na atom kisika, ili amino zaštitna skupina kada su vezani za atom dušika ili dva R3 skupine povezane na atom dušika spojene su u heterociklički prsten;
svaka instanca XAA je, neovisno, prirodna ili neprirodna α-amino kiselina;
y je, neovisno, 1 do 8;
s je 0, 1, ili 2;
j je, neovisno, integer između 1 do 10;
p je, neovisno, integer između 1 do 2;
svaka instanca q je neovisno 0, 1, ili 2;
v je, neovisno, integer između 0 do 1;
svaka instanca t, w, i z je, neovisno, integer između 0 i 100; i
[image]
odgovara jednostrukoj, dvostrukoj ili trostrukoj vezi.
2. Polipeptid iz zahtjeva 1, pri čemu polipeptid jepolipeptid je izabran iz skupine koja se sastoji od formula:
[image]
[image]
[image]
[image]
[image]
i njegove soli i stereoizomeri.
3. Polipeptid iz zahtjeva 1, pri čemu polipeptid je:
[image]
ili njegova sol.
4. Polipeptid iz zahtjeva 1, pri čemu polipeptid je:
[image]
ili njegova sol.
5. Polipeptid iz zahtjeva 1, pri čemu polipeptid je:
[image]
ili njegova sol.
6. Polipeptid iz zahtjeva 1, pri čemu polipeptid je:
[image]
ili njegova sol.
7. Polipeptid iz zahtjeva 1, pri čemu polipeptid ima formulu (II):
[image]
ili njegova sol ili stereoizomer.
8. Polipeptid iz zahtjeva 1, pri čemu polipeptid ima formulu (I):
[image]
ili njegova sol ili stereoizomer.
9. Polipetid iz bilo kojeg od zahtjeva 1 do 8, pri čemu y je 2.
10. Polipetid iz bilo kojeg od zahtjeva 1 do 8, pri čemu y je 3.
11. Polipetid iz bilo kojeg od zahtjeva 1 do 8, pri čemu y je 4.
12. Polipetid iz bilo kojeg od zahtjeva 1 do 8, pri čemu y je 5.
13. Polipetid iz bilo kojeg od zahtjeva 1 do 8, pri čemu y je 6.
14. Polipetid iz bilo kojeg od zahtjeva 1 do 8, pri čemu v je 0.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261705950P | 2012-09-26 | 2012-09-26 | |
| US201361789157P | 2013-03-15 | 2013-03-15 | |
| PCT/US2013/062004 WO2014052647A2 (en) | 2012-09-26 | 2013-09-26 | Proline-locked stapled peptides and uses thereof |
| EP13777368.5A EP2920197B1 (en) | 2012-09-26 | 2013-09-26 | Proline-locked stapled peptides and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210707T1 true HRP20210707T1 (hr) | 2021-09-17 |
Family
ID=49382577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210707TT HRP20210707T1 (hr) | 2012-09-26 | 2021-05-06 | Prolinom blokirani označeni peptidi i njihova uporaba |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US9617309B2 (hr) |
| EP (2) | EP2920197B1 (hr) |
| JP (3) | JP6506166B2 (hr) |
| CA (2) | CA3113959A1 (hr) |
| CY (1) | CY1125259T1 (hr) |
| DK (1) | DK2920197T3 (hr) |
| ES (1) | ES2874525T3 (hr) |
| HK (1) | HK1213269A1 (hr) |
| HR (1) | HRP20210707T1 (hr) |
| HU (1) | HUE054444T2 (hr) |
| IL (4) | IL237967B (hr) |
| LT (1) | LT2920197T (hr) |
| PL (1) | PL2920197T3 (hr) |
| PT (1) | PT2920197T (hr) |
| RS (1) | RS61957B1 (hr) |
| SI (1) | SI2920197T1 (hr) |
| WO (1) | WO2014052647A2 (hr) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7192713B1 (en) | 1999-05-18 | 2007-03-20 | President And Fellows Of Harvard College | Stabilized compounds having secondary structure motifs |
| JP5649825B2 (ja) | 2007-01-31 | 2015-01-07 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | 安定化させたｐ５３ペプチドおよびその使用法 |
| KR101525754B1 (ko) | 2007-03-28 | 2015-06-09 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 스티칭된 폴리펩티드 |
| WO2010011313A2 (en) | 2008-07-23 | 2010-01-28 | President And Fellows Of Harvard College | Ligation of stapled polypeptides |
| JP2012515172A (ja) | 2009-01-14 | 2012-07-05 | エルロン・セラピューティクス・インコーポレイテッド | ペプチド模倣大環状分子 |
| JP2012532929A (ja) | 2009-07-13 | 2012-12-20 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | 二機能性のステープリングされたポリペプチドおよびそれらの使用 |
| US20130072439A1 (en) | 2009-09-22 | 2013-03-21 | Huw M. Nash | Peptidomimetic macrocycles |
| CN108570097A (zh) | 2010-08-13 | 2018-09-25 | 爱勒让治疗公司 | 拟肽大环化合物 |
| US9487562B2 (en) | 2011-06-17 | 2016-11-08 | President And Fellows Of Harvard College | Stabilized polypeptides as regulators of RAB GTPase function |
| MX358886B (es) | 2011-10-18 | 2018-08-31 | Aileron Therapeutics Inc | Macrociclos peptidomimeticos. |
| SG11201404648PA (en) | 2012-02-15 | 2014-09-26 | Aileron Therapeutics Inc | Peptidomimetic macrocycles |
| US8987414B2 (en) | 2012-02-15 | 2015-03-24 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
| WO2014052647A2 (en) * | 2012-09-26 | 2014-04-03 | President And Fellows Of Harvard College | Proline-locked stapled peptides and uses thereof |
| EP2914256B1 (en) | 2012-11-01 | 2019-07-31 | Aileron Therapeutics, Inc. | Disubstituted amino acids and methods of preparation and use thereof |
| WO2014138429A2 (en) | 2013-03-06 | 2014-09-12 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and use thereof in regulating hif1alpha |
| CN110105434A (zh) | 2013-03-13 | 2019-08-09 | 哈佛大学的校长及成员们 | 钉合且缝合的多肽及其用途 |
| WO2014201370A1 (en) | 2013-06-14 | 2014-12-18 | President And Fellows Of Harvard College | Stabilized polypeptide insulin receptor modulators |
| JP6759109B2 (ja) | 2014-05-21 | 2020-09-23 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Ｒａｓ抑制性ペプチドおよびその使用 |
| CN112972378A (zh) | 2014-09-24 | 2021-06-18 | 艾瑞朗医疗公司 | 拟肽大环化合物及其制剂 |
| JP2017533889A (ja) | 2014-09-24 | 2017-11-16 | エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ペプチド模倣大環状分子およびその使用 |
| WO2016085280A1 (ko) * | 2014-11-28 | 2016-06-02 | 서울대학교산학협력단 | 세포 투과성 스테이플 펩타이드, 이의 제조방법 및 그 용도 |
| EP3294318A4 (en) | 2015-03-20 | 2019-04-03 | Aileron Therapeutics, Inc. | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF |
| US10059741B2 (en) | 2015-07-01 | 2018-08-28 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| US10023613B2 (en) | 2015-09-10 | 2018-07-17 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles as modulators of MCL-1 |
| CN110799493B (zh) * | 2017-06-29 | 2021-07-06 | 广州南沙龙沙有限公司 | 制备α-甲基-L-脯氨酸的方法 |
| SG11202001162TA (en) | 2017-09-07 | 2020-03-30 | Fog Pharmaceuticals Inc | Agents modulating beta-catenin functions and methods thereof |
| US11795196B2 (en) | 2017-12-15 | 2023-10-24 | Stealth Biotherapeutics Inc. | Mitochondria-targeting peptides |
| US20200354413A1 (en) | 2017-12-15 | 2020-11-12 | Dana-Farber Cancer Institute, Inc. | Stabilized peptide-mediated targeted protein degradation |
| DK3723783T3 (da) * | 2017-12-15 | 2023-03-20 | Stealth Biotherapeutics Inc | Mitokondrie-målrettede peptider |
| EP3749678A1 (en) | 2018-02-07 | 2020-12-16 | Dana Farber Cancer Institute, Inc. | Cell-permeable stapled peptide modules for cellular delivery |
| US11091522B2 (en) | 2018-07-23 | 2021-08-17 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| JP2022542882A (ja) | 2019-07-24 | 2022-10-07 | ステルス バイオセラピューティクス インコーポレイテッド | 神経変性疾患の治療におけるペプチド模倣化合物（ｒ）－２－アミノ－ｎ－（（ｓ）－ｌ－（（（ｓ）－５－アミノ－ｌ－（３－ベンジル－１，２，４－オキサジアゾール－５－イル）ペンチル）アミノ）－３－（４－ヒドロキシ－２，６－ジメチルフェニル）－ｉ－オキソプロパン－２－イル）－５－グアニジノペンタンアミド |
| EP4121082A4 (en) * | 2020-03-17 | 2024-05-01 | Fog Pharmaceuticals Inc | STAPLED HELICAL PEPTIDES AND THEIR USES |
| AU2021360898A1 (en) | 2020-10-14 | 2023-03-23 | Dana-Farber Cancer Institute, Inc. | Chimeric conjugates for degradation of viral and host proteins and methods of use |
| KR102520353B1 (ko) * | 2021-01-13 | 2023-04-12 | 동국대학교 산학협력단 | 안정화된 폴리프롤린 ⅱ 나선구조를 갖는 펩타이드 |
Family Cites Families (116)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4270537A (en) | 1979-11-19 | 1981-06-02 | Romaine Richard A | Automatic hypodermic syringe |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4730006A (en) | 1986-01-27 | 1988-03-08 | Merrell Dow Pharmaceuticals Inc. | Derivatives of 2,6-diamino-3-haloheptanedioic acid |
| US4886499A (en) | 1986-12-18 | 1989-12-12 | Hoffmann-La Roche Inc. | Portable injection appliance |
| GB8704027D0 (en) | 1987-02-20 | 1987-03-25 | Owen Mumford Ltd | Syringe needle combination |
| US4940460A (en) | 1987-06-19 | 1990-07-10 | Bioject, Inc. | Patient-fillable and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US5339163A (en) | 1988-03-16 | 1994-08-16 | Canon Kabushiki Kaisha | Automatic exposure control device using plural image plane detection areas |
| EP0360390A1 (en) * | 1988-07-25 | 1990-03-28 | Glaxo Group Limited | Spirolactam derivatives |
| FR2638359A1 (fr) | 1988-11-03 | 1990-05-04 | Tino Dalto | Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau |
| US5120859A (en) | 1989-09-22 | 1992-06-09 | Genentech, Inc. | Chimeric amino acid analogues |
| US5712418A (en) | 1989-10-23 | 1998-01-27 | Research Corporation Technologies, Inc. | Synthesis and use of amino acid fluorides as peptide coupling reagents |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5190521A (en) | 1990-08-22 | 1993-03-02 | Tecnol Medical Products, Inc. | Apparatus and method for raising a skin wheal and anesthetizing skin |
| US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
| US5364851A (en) | 1991-06-14 | 1994-11-15 | International Synthecon, Llc | Conformationally restricted biologically active peptides, methods for their production and uses thereof |
| GB9118204D0 (en) | 1991-08-23 | 1991-10-09 | Weston Terence E | Needle-less injector |
| SE9102652D0 (sv) | 1991-09-13 | 1991-09-13 | Kabi Pharmacia Ab | Injection needle arrangement |
| US5328483A (en) | 1992-02-27 | 1994-07-12 | Jacoby Richard M | Intradermal injection device with medication and needle guard |
| CA2196061C (en) | 1992-04-03 | 2000-06-13 | Robert H. Grubbs | High activity ruthenium or osmium metal carbene complexes for olefin metathesis reactions and synthesis thereof |
| US5411860A (en) | 1992-04-07 | 1995-05-02 | The Johns Hopkins University | Amplification of human MDM2 gene in human tumors |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
| US5334144A (en) | 1992-10-30 | 1994-08-02 | Becton, Dickinson And Company | Single use disposable needleless injector |
| US5446128A (en) | 1993-06-18 | 1995-08-29 | The Board Of Trustees Of The University Of Illinois | Alpha-helix mimetics and methods relating thereto |
| US5622852A (en) | 1994-10-31 | 1997-04-22 | Washington University | Bcl-x/Bcl-2 associated cell death regulator |
| WO1995024176A1 (en) | 1994-03-07 | 1995-09-14 | Bioject, Inc. | Ampule filling device |
| US5466220A (en) | 1994-03-08 | 1995-11-14 | Bioject, Inc. | Drug vial mixing and transfer device |
| US5824483A (en) | 1994-05-18 | 1998-10-20 | Pence Inc. | Conformationally-restricted combinatiorial library composition and method |
| US6407059B1 (en) | 1994-06-08 | 2002-06-18 | Peptor Limited | Conformationally constrained backbone cyclized peptide analogs |
| IL109943A (en) | 1994-06-08 | 2006-08-01 | Develogen Israel Ltd | Conformationally constrained backbone cyclized peptide analogs |
| US5770377A (en) | 1994-07-20 | 1998-06-23 | University Of Dundee | Interruption of binding of MDM2 and P53 protein and therapeutic application thereof |
| ATE544776T1 (de) | 1994-12-29 | 2012-02-15 | Massachusetts Inst Technology | Chimäre dna-bindeproteine |
| US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
| MX9708500A (es) | 1995-05-04 | 1998-02-28 | Scripps Research Inst | Sintesis de proteinas mediante ligacion quimica nativa. |
| US6184344B1 (en) | 1995-05-04 | 2001-02-06 | The Scripps Research Institute | Synthesis of proteins by native chemical ligation |
| US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
| US6051554A (en) | 1995-06-07 | 2000-04-18 | Peptor Limited | Conformationally constrained backbone cyclized somatostatin analogs |
| US5811515A (en) | 1995-06-12 | 1998-09-22 | California Institute Of Technology | Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis |
| US5893397A (en) | 1996-01-12 | 1999-04-13 | Bioject Inc. | Medication vial/syringe liquid-transfer apparatus |
| GB9607549D0 (en) | 1996-04-11 | 1996-06-12 | Weston Medical Ltd | Spring-powered dispensing device |
| US5663316A (en) | 1996-06-18 | 1997-09-02 | Clontech Laboratories, Inc. | BBC6 gene for regulation of cell death |
| US7083983B2 (en) | 1996-07-05 | 2006-08-01 | Cancer Research Campaign Technology Limited | Inhibitors of the interaction between P53 and MDM2 |
| US5955593A (en) | 1996-09-09 | 1999-09-21 | Washington University | BH3 interacting domain death agonist |
| US20020064546A1 (en) | 1996-09-13 | 2002-05-30 | J. Milton Harris | Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor |
| US5965703A (en) | 1996-09-20 | 1999-10-12 | Idun Pharmaceuticals | Human bad polypeptides, encoding nucleic acids and methods of use |
| US5856445A (en) | 1996-10-18 | 1999-01-05 | Washington University | Serine substituted mutants of BCL-XL /BCL-2 associated cell death regulator |
| US6271198B1 (en) | 1996-11-06 | 2001-08-07 | Genentech, Inc. | Constrained helical peptides and methods of making same |
| AU734337B2 (en) | 1996-11-21 | 2001-06-14 | Promega Corporation | Alkyl peptide amides and applications |
| US6849428B1 (en) | 1997-03-05 | 2005-02-01 | New England Biolabs, Inc. | Intein-mediated protein ligation of expressed proteins |
| US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
| EP1015578A4 (en) | 1997-09-17 | 2004-12-01 | Walker And Eliza Hall Inst Of | THERAPEUTIC MOLECULES |
| US6165732A (en) | 1997-10-14 | 2000-12-26 | Washington University | Method for identifying apoptosis modulating compounds |
| US6875594B2 (en) | 1997-11-13 | 2005-04-05 | The Rockefeller University | Methods of ligating expressed proteins |
| US6362276B1 (en) | 1998-01-07 | 2002-03-26 | Debio Recherche Pharmaceutique S.A. | Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom |
| IT1298087B1 (it) | 1998-01-08 | 1999-12-20 | Fiderm S R L | Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni |
| AU767185B2 (en) | 1998-03-23 | 2003-11-06 | President And Fellows Of Harvard College | Synthesis of compounds and libraries of compounds |
| US6326354B1 (en) | 1998-08-19 | 2001-12-04 | Washington University | Modulation of apoptosis with bid |
| US7173005B2 (en) | 1998-09-02 | 2007-02-06 | Antyra Inc. | Insulin and IGF-1 receptor agonists and antagonists |
| IL145406A0 (en) | 1999-03-29 | 2002-06-30 | Procter & Gamble | Melanocortin receptor ligands |
| US6444425B1 (en) | 1999-04-02 | 2002-09-03 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
| US6713280B1 (en) | 1999-04-07 | 2004-03-30 | Thomas Jefferson University | Enhancement of peptide cellular uptake |
| US7192713B1 (en) | 1999-05-18 | 2007-03-20 | President And Fellows Of Harvard College | Stabilized compounds having secondary structure motifs |
| US6348558B1 (en) | 1999-12-10 | 2002-02-19 | Shearwater Corporation | Hydrolytically degradable polymers and hydrogels made therefrom |
| US7049290B2 (en) | 2000-07-28 | 2006-05-23 | Universität Zürich | Essential downstream component of the wingless signaling pathway and therapeutic and diagnostic applications based thereon |
| US6703382B2 (en) | 2000-08-16 | 2004-03-09 | Georgetown University Medical Center | Small molecule inhibitors targeted at Bcl-2 |
| EP1343884A2 (en) | 2000-12-19 | 2003-09-17 | The Johns Hopkins University | Jfy1 protein induces rapid apoptosis |
| EP1469871A4 (en) | 2001-12-31 | 2006-08-23 | Dana Farber Cancer Inst Inc | METHOD FOR TREATING APOPTOSIS AND COMPOSITIONS THEREFOR |
| WO2003089906A2 (en) | 2002-04-22 | 2003-10-30 | University Of Florida | Functionalized nanoparticles and methods of use |
| SE0201863D0 (en) | 2002-06-18 | 2002-06-18 | Cepep Ab | Cell penetrating peptides |
| WO2004022580A2 (en) | 2002-09-09 | 2004-03-18 | Dana-Farber Cancer Institute, Inc. | Bh3 peptides and method of use thereof |
| PL210871B1 (pl) | 2002-11-08 | 2012-03-30 | Hoffmann La Roche | Pochodne oksazolu, sposób ich wytwarzania, środki farmaceutyczne i zastosowanie pochodnych oksazolu |
| US20070032417A1 (en) | 2002-12-24 | 2007-02-08 | Walter And Eliza Hall Institute Of Medical Research | Peptides and therapeutic uses thereof |
| JP2006523213A (ja) * | 2003-03-20 | 2006-10-12 | ニューレン ファーマシューティカルズ リミテッド | 神経保護大環状化合物及びそれらの使用方法 |
| JP2007537989A (ja) | 2003-10-16 | 2007-12-27 | アプラーゲン ゲゼルシャフト ミット ベシュレンクテル ハフツング | 安定化ペプチド |
| ITMI20032102A1 (it) * | 2003-10-30 | 2005-04-30 | Univ Degli Studi Milano | Composti peptidomimetici, procedimento stereoselettivo per la loro preparazione, loro uso come intermedi di sintesi di derivati biologicamente attivi. |
| PT2332968T (pt) | 2003-11-05 | 2016-08-17 | Harvard College | Péptidos alfa-helicoidais adequados para a activação ou inibição da morte celular |
| GB0404731D0 (en) | 2004-03-03 | 2004-04-07 | Indp Administrative Inst Nims | Method and products for the selective degradation of proteins |
| WO2005090388A1 (en) | 2004-03-19 | 2005-09-29 | The University Of Queensland | Alpha helical mimics, their uses and methods for their production |
| US7202332B2 (en) | 2004-05-27 | 2007-04-10 | New York University | Methods for preparing internally constrained peptides and peptidomimetics |
| US7501397B2 (en) | 2004-06-04 | 2009-03-10 | The Brigham And Women's Hospital, Inc. | Helical peptidomimetics with enhanced activity |
| EP1828246A1 (en) * | 2004-12-20 | 2007-09-05 | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. | Myd88 homodimerization inhibitors |
| US20060148715A1 (en) | 2004-12-20 | 2006-07-06 | Baylor College Of Medicine | Structural requirements for STAT3 binding and recruitment to phosphotyrosine ligands |
| WO2006103666A2 (en) | 2005-03-28 | 2006-10-05 | Yeda Research And Development Co. Ltd. | Isolated bid polypeptides, polynucleotides encoding same and antibodies directed thereagainst and methods of using same for inducing cell cycle arrest or apoptosis |
| GB0511771D0 (en) * | 2005-06-09 | 2005-07-20 | Novartis Ag | Organic compounds |
| US7745573B2 (en) | 2006-02-17 | 2010-06-29 | Polychip Pharmaceuticals Pty Ltd. | Conotoxin analogues and methods for synthesis of intramolecular dicarba bridge-containing peptides |
| US7538190B2 (en) | 2006-02-17 | 2009-05-26 | Polychip Pharmaceuticals Pty Ltd | Methods for the synthesis of two or more dicarba bridges in organic compounds |
| GB0611405D0 (en) | 2006-06-09 | 2006-07-19 | Univ Belfast | FKBP-L: A novel inhibitor of angiogenesis |
| CA2669696A1 (en) | 2006-11-15 | 2008-05-22 | Dana-Farber Cancer Institute, Inc. | Stabilized maml peptides and uses thereof |
| US7981998B2 (en) | 2006-12-14 | 2011-07-19 | Aileron Therapeutics, Inc. | Bis-sulfhydryl macrocyclization systems |
| CN105061577A (zh) | 2006-12-14 | 2015-11-18 | 爱勒让治疗公司 | 双巯基大环化系统 |
| JP5649825B2 (ja) | 2007-01-31 | 2015-01-07 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | 安定化させたｐ５３ペプチドおよびその使用法 |
| BRPI0807578A2 (pt) | 2007-02-23 | 2021-06-15 | Aileron Therapeutics, Inc. | macrociclo peptidomimético, composto, kit e métodos para sintetizar um macrociclo peptidomimético |
| KR101525754B1 (ko) | 2007-03-28 | 2015-06-09 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 스티칭된 폴리펩티드 |
| WO2009042237A2 (en) | 2007-09-26 | 2009-04-02 | Dana Farber Cancer Institute | Methods and compositions for modulating bcl-2 family polypeptides |
| US20110144303A1 (en) | 2008-04-08 | 2011-06-16 | Aileron Therapeutics, Inc. | Biologically Active Peptidomimetic Macrocycles |
| EP2310407A4 (en) | 2008-04-08 | 2011-09-14 | Aileron Therapeutics Inc | BIOLOGIC EFFECTIVE PEPTIDOMIMETIC MACROCYCLES |
| WO2010011313A2 (en) | 2008-07-23 | 2010-01-28 | President And Fellows Of Harvard College | Ligation of stapled polypeptides |
| CA2737918A1 (en) | 2008-09-22 | 2010-03-25 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| EP2342222B1 (en) | 2008-09-22 | 2018-03-21 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| JP2012509902A (ja) | 2008-11-24 | 2012-04-26 | エルロン・セラピューティクス・インコーポレイテッド | 改善された特性を有するペプチド模倣大環状分子 |
| JP5731986B2 (ja) | 2008-12-09 | 2015-06-10 | ダナ ファーバー キャンサー インスティテュート インコーポレイテッド | Ｍｃｌ−１の特異的調節の方法及び組成物 |
| WO2010132869A2 (en) * | 2009-05-15 | 2010-11-18 | Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use |
| DE102009032902A1 (de) * | 2009-07-10 | 2011-01-13 | Forschungsverbund Berlin E.V. | Induktion von α-Helix-Konformationen in Proteinen und Peptiden |
| JP2012532929A (ja) | 2009-07-13 | 2012-12-20 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | 二機能性のステープリングされたポリペプチドおよびそれらの使用 |
| AU2010306718A1 (en) | 2009-10-14 | 2012-05-24 | Aileron Therapeutics, Inc. | Improved peptidomimetic macrocycles |
| CN102812167A (zh) * | 2009-12-30 | 2012-12-05 | 阿维拉制药公司 | 蛋白的配体-介导的共价修饰 |
| WO2011163423A2 (en) | 2010-06-22 | 2011-12-29 | University Of Central Florida Research Foundation, Inc. | Methods and compositions for cell permeable stat3 inhibitor |
| WO2012040459A2 (en) | 2010-09-22 | 2012-03-29 | President And Fellows Of Harvard College | Beta-catenin targeting peptides and uses thereof |
| US9487562B2 (en) | 2011-06-17 | 2016-11-08 | President And Fellows Of Harvard College | Stabilized polypeptides as regulators of RAB GTPase function |
| EP2721061A4 (en) | 2011-06-17 | 2014-11-05 | Harvard College | STABILIZED VARIANT MAML PEPTIDES AND USES THEREOF |
| WO2014052647A2 (en) * | 2012-09-26 | 2014-04-03 | President And Fellows Of Harvard College | Proline-locked stapled peptides and uses thereof |
| US20150225471A1 (en) | 2012-10-01 | 2015-08-13 | President And Fellows Of Harvard College | Stabilized polypeptide insulin receptor modulators |
| CN110105434A (zh) | 2013-03-13 | 2019-08-09 | 哈佛大学的校长及成员们 | 钉合且缝合的多肽及其用途 |
-
2013
- 2013-09-26 WO PCT/US2013/062004 patent/WO2014052647A2/en active Application Filing
- 2013-09-26 PT PT137773685T patent/PT2920197T/pt unknown
- 2013-09-26 SI SI201331878T patent/SI2920197T1/sl unknown
- 2013-09-26 CA CA3113959A patent/CA3113959A1/en active Pending
- 2013-09-26 EP EP13777368.5A patent/EP2920197B1/en active Active
- 2013-09-26 ES ES13777368T patent/ES2874525T3/es active Active
- 2013-09-26 EP EP21155269.0A patent/EP3872067A1/en active Pending
- 2013-09-26 LT LTEP13777368.5T patent/LT2920197T/lt unknown
- 2013-09-26 HU HUE13777368A patent/HUE054444T2/hu unknown
- 2013-09-26 CA CA2925035A patent/CA2925035C/en active Active
- 2013-09-26 PL PL13777368T patent/PL2920197T3/pl unknown
- 2013-09-26 RS RS20210714A patent/RS61957B1/sr unknown
- 2013-09-26 JP JP2015534667A patent/JP6506166B2/ja active Active
- 2013-09-26 DK DK13777368.5T patent/DK2920197T3/da active
- 2013-09-26 US US14/431,280 patent/US9617309B2/en active Active
-
2015
- 2015-03-26 IL IL237967A patent/IL237967B/en active IP Right Grant
-
2016
- 2016-01-26 HK HK16100862.7A patent/HK1213269A1/zh unknown
-
2017
- 2017-03-10 US US15/456,070 patent/US20180009847A1/en not_active Abandoned
-
2018
- 2018-11-20 IL IL263145A patent/IL263145A/en unknown
-
2019
- 2019-03-28 JP JP2019062248A patent/JP7435991B2/ja active Active
-
2020
- 2020-04-26 IL IL274236A patent/IL274236B/en active IP Right Grant
-
2021
- 2021-05-06 HR HRP20210707TT patent/HRP20210707T1/hr unknown
- 2021-05-12 IL IL283139A patent/IL283139A/en unknown
- 2021-06-08 CY CY20211100497T patent/CY1125259T1/el unknown
- 2021-09-06 JP JP2021144616A patent/JP7448966B2/ja active Active
-
2022
- 2022-02-25 US US17/681,248 patent/US20220177522A1/en not_active Abandoned
-
2023
- 2023-08-21 US US18/453,118 patent/US20240124525A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210707T1 (hr) | Prolinom blokirani označeni peptidi i njihova uporaba | |
| JP2019142886A5 (hr) | ||
| HRP20171058T1 (hr) | Derivati dipeptida lizinske glutaminske kiseline | |
| HRP20210342T1 (hr) | Pripravci glikopeptida | |
| BR112014029972A2 (pt) | reagentes de conjugação | |
| EA201490582A1 (ru) | Пирролбензодиазепины и конъюгаты направленного действия | |
| HRP20211116T1 (hr) | Derivati inozitola za upotrebu u patološkoj kristalizaciji | |
| EP3725801A3 (en) | Amino diacids containing peptide modifiers | |
| TR201820824T4 (tr) | IL-12, IL-23 ve/veya IFN-alfa'nın modülatörleri olarak faydalı amid ile sübstitüe edilmiş heterosiklik bileşikler. | |
| AR057032A1 (es) | Tigeciclina y metodos de preparacion | |
| BR112015010244A2 (pt) | compostos de piridila substituída por alquil-amida úteis como moduladores de il-12, il-23 e/ou respostas de ifnalfa | |
| DE602005008996D1 (de) | Radiofluorierte peptide | |
| UA115043C2 (uk) | Амідні похідні n-карбамідзаміщених амінокислот як модулятори формілпептидного рецептора 1 (fprl-1) | |
| HRP20161145T1 (hr) | Postupak za pripravu l-argininske soli perindoprila | |
| HRP20210723T1 (hr) | Kontrastna sredstva za magnetsku rezonancu na bazi mangana | |
| BR112018011030A2 (pt) | ?composto, mistura, composição, formulação elastomérica vulcanizável, artigo elastomérico vulcanizado, e, pneu de veículo? | |
| WO2013098802A3 (en) | Solid phase peptide synthesis via side chain attachment of hydroxyl amino acids | |
| RU2014141547A (ru) | Аминокислоты-липиды | |
| CL2015000419A1 (es) | Material adhesivo de laminación de dos componentes (2–c) | |
| CO6420338A2 (es) | Compuesto ciclico que contiene heteroatomos | |
| BR112012029954A2 (pt) | composto de poliamida | |
| UY31836A (es) | Nuevo ácido l-glurámico marcado con [f-18] y derivados de l-glutamina marcada con [f-18] (ii), su uso y procedimientos para su preparación | |
| RS53772B1 (en) | ALISKIREN SYNTHESIS | |
| ES2570379T3 (es) | Copolímeros para composiciones de revestimiento sensibles a radiación en el infrarrojo cercano para planchas de impresión litográfica térmicas positivas | |
| MX337438B (es) | Colorantes acidos. |